Figure 2.

MTS assay in hSCs maintained up to 7 days of treatment in vitro (DIV) in presence or absence of muscarinic agonists. (A) APE (100 µM) exposure was able to decrease cell growth up to 7 days of treatment (**** p < 0.0001; APE vs. ctrl at the same time point). The treatment with 100 µM muscarine appeared to promote cell proliferation after 5 days of treatment (**** p < 0.0001; muscarine vs. ctrl at the same time point). Data are represented as mean ± SEM of three independent experiments performed in triplicate in five different patients. One-way ANOVA with Tukey’s post hoc test between different time points is reported in the Supplementary Materials. (B) hSCs cell growth was also evaluated at different APE concentrations (25, 50, and 100 µM) at 3, 5, and 7 DIV. ANOVA with Dunnett multiple comparison analyses was performed against control at the same time point. Data are represented as mean ± SEM of three independent experiments performed in triplicate in five different patients (**** p < 0.0001; * p < 0.05). The red bar represents the number of cells plated (20 × 10³ cells/well). The day after plating, cells were treated with both muscarinic agonists at the final concentration of 100 µM (A) or with different concentrations of APE (B); MTS assays were performed after 3, 5, and 7 days of treatment.